Skip to main content
Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · IEX Real-Time Price · USD
3.460
-0.050 (-1.42%)
At close: Apr 18, 2024, 4:00 PM
3.350
-0.110 (-3.18%)
After-hours: Apr 18, 2024, 4:06 PM EDT

Allogene Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 202320222021202020192018
Revenue
0.10.16114.09000
Revenue Growth (YoY)
-39.10%-99.86%----
Gross Profit
0.10.16114.09000
Selling, General & Admin
71.6779.3174.1165.2657.4740.98
Research & Development
242.91256.39220.18192.99144.54151.86
Other Operating Expenses
13.2500000
Operating Expenses
327.83335.69294.28258.24202.01192.84
Operating Income
-327.74-335.54-180.19-258.24-202.01-192.84
Interest Expense / Income
000003.36
Other Expense / Income
-0.474.881.8658.14-17.0815.42
Pretax Income
-327.27-340.41-182.05-316.38-184.93-211.62
Income Tax
0000-0.33-0.12
Net Income
-327.27-340.41-182.05-316.38-184.59-211.51
Shares Outstanding (Basic)
15714313612010129
Shares Outstanding (Diluted)
15714313612010129
Shares Change
9.63%5.39%12.84%19.11%249.11%-
EPS (Basic)
-2.09-2.38-1.34-2.63-1.83-7.31
EPS (Diluted)
-2.09-2.38-1.34-2.63-1.83-7.31
Free Cash Flow
-239.25-225.71-206.26-181.05-188.14-47.89
Free Cash Flow Per Share
-1.52-1.58-1.52-1.50-1.86-1.65
Gross Margin
100.00%100.00%100.00%---
Operating Margin
-344986.32%-215087.18%-157.94%---
Profit Margin
-344489.47%-218214.10%-159.57%---
Free Cash Flow Margin
-251841.05%-144685.90%-180.79%---
EBITDA
-313.07-326.12-171.6-308.95-180.5-207.22
EBITDA Margin
-329543.16%-209050.64%-150.41%---
Depreciation & Amortization
14.214.310.457.444.421.05
EBIT
-327.27-340.41-182.05-316.38-184.93-208.26
EBIT Margin
-344489.47%-218214.10%-159.57%---
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).